NORTH AMERICA OPHTHALMIC DRUGS & DEVICES MARKET FORECAST 2017-2025
KEY FINDINGS
North America ophthalmic drugs & devices market was valued at $19956.50 million in 2016 and is expected to reach $31893.42 million by 2025 growing at a CAGR of 5.36% during the forecast period of 2017-2025. The ophthalmic drugs and devices market is driven by factors like increase in FDA approvals which gives a boost in the adoption of drugs and devices and rise in surgeries in ophthalmology market due to the high dominance of refractive errors.
MARKET INSIGHTS
The North America ophthalmic drugs & devices market is segmented by ophthalmic devices, surgery devices, vision care, by type of diseases, by therapeutics and by geography atrophy. Globally increase in geriatric population, rise in the number of eye disorders, increase in healthcare expenditure and rise in adoption of minimally invasive surgeries have contributed to the growth of the market.
Well-known drugs are going off patent and key players affected by the delay in new drugs coming into the market are the two factors restricting the growth of the market. The market faces challenges in risk associated with the ocular diseases and lack of awareness among people regarding ophthalmology.
COMPETITIVE INSIGHTS
Global ophthalmic drugs market has a large number of market players but the market is dominated by companies like Novartis AG and Santen.
North America ophthalmic drugs & devices market was valued at $19956.50 million in 2016 and is expected to reach $31893.42 million by 2025 growing at a CAGR of 5.36% during the forecast period of 2017-2025. The ophthalmic drugs and devices market is driven by factors like increase in FDA approvals which gives a boost in the adoption of drugs and devices and rise in surgeries in ophthalmology market due to the high dominance of refractive errors.
MARKET INSIGHTS
The North America ophthalmic drugs & devices market is segmented by ophthalmic devices, surgery devices, vision care, by type of diseases, by therapeutics and by geography atrophy. Globally increase in geriatric population, rise in the number of eye disorders, increase in healthcare expenditure and rise in adoption of minimally invasive surgeries have contributed to the growth of the market.
Well-known drugs are going off patent and key players affected by the delay in new drugs coming into the market are the two factors restricting the growth of the market. The market faces challenges in risk associated with the ocular diseases and lack of awareness among people regarding ophthalmology.
COMPETITIVE INSIGHTS
Global ophthalmic drugs market has a large number of market players but the market is dominated by companies like Novartis AG and Santen.
1 RESEARCH SCOPE
1.1 STUDY GOALS
1.2 SCOPE OF MARKET STUDY
1.3 WHO WILL FIND THIS REPORT USEFUL?
1.4 STUDY AND FORECASTING YEARS
2 RESEARCH METHODOLOGY
2.1 SOURCES OF DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 TOP DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 DATA TRIANGULATION
3 EXECUTIVE SUMMARY
3.1 KEY FINDINGS
4 MARKET OVERVIEW
4.1 MARKET DEFINITION AND SCOPE
4.2 TOP OPHTHALMIC DRUGS BRANDS
5 MARKET DETERMINANTS
5.1 MARKET DRIVERS
5.1.1 INCREASING FDA APPROVALS GIVING A BOOST TO ADOPTION OF DRUGS AND DEVICES
5.1.2 SURGERIES IN OPHTHALMOLOGY MARKET ON RISE DUE TO HIGH PREVALENCE RATE OF REFRACTIVE ERRORS
5.1.3 INCREASING GERIATRIC POPULATION GLOBALLY
5.1.4 RISING PREVALENCE OF EYE DISORDERS
5.1.5 INCREASED HEALTHCARE EXPENDITURE
5.1.6 MINIMALLY INVASIVE SURGERIES ADOPTION ON RISE
5.2 MARKET RESTRAINTS
5.2.1 RENOWNED DRUGS GOING OFF PATENT
5.2.2 MAJOR PLAYERS AFFECTED BY DRYING PIPELINES
5.3 MARKET OPPORTUNITIES
5.3.1 GROWING OPPORTUNITIES IN DEVELOPING ECONOMIES
5.3.2 EMERGING MARKETS PRESENT REMARKABLE GROWTH OPPORTUNITIES
5.4 MARKET CHALLENGES
5.4.1 RISK ASSOCIATED WITH THE OCULAR DISEASES
5.4.2 LACK OF AWARENESS
6 MARKET SEGMENTATION
6.1 BY OPHTHALMIC DEVICES
6.1.1 DIAGNOSTIC & MONITORING EQUIPMENT
6.1.1.1 OPTICAL COHERENCE TOMOGRAPHY SCANNERS
6.1.1.2 OPHTHALMIC ULTRA SOUND IMAGING SYSTEMS
6.1.1.3 FUNDUS CAMERA
6.1.1.4 OPHTHALMOSCOPES
6.1.1.5 RETINOSCOPE
6.1.1.6 PACHYMETER
6.1.1.7 WAVEFRONT ABERROMETERS
6.1.1.8 PERIMETERS/VISUAL FIELD ANALYZER
6.1.1.9 AUTOREFRACTORS/PHOROPTER
6.1.1.10 KERATOMETERS
6.1.1.11 SPECULAR MICROSCOPE
6.1.1.12 CORNEAL TOPOGHAPHERS
6.1.1.13 TONOMETERS
6.1.1.14 SLIT LAMPS
6.1.1.15 BIOMETERS
6.1.1.16 OTHER
6.1.2 SURGERY DEVICE
6.1.2.1 CATARACT SURGERY DEVICE
6.1.2.1.1 INTRAOCULAR LENS
6.1.2.1.2 PHACOEMULSIFICATION DEVICES
6.1.2.1.3 OPHTHALMIC VISCOELASTIC DEVICES
6.1.2.2 GLAUCOMA SURGERY DEVICE
6.1.2.2.1 STENTS AND IMPLANT
6.1.2.2.2 GLAUCOMA DRAINAGE DEVICE
6.1.2.2.3 GLAUCOMA SYSTEM
6.1.2.2.4 GLAUCOMA LASER
6.1.2.3 REFRACTIVE SURGERY DEVICE
6.1.2.3.1 EXCIMER LASER
6.1.2.3.2 EMCROKERATOME
6.1.2.3.3 FEMTOSECOND LASER
6.1.2.3.4 YAG LASER
6.1.2.4 VITREORETINAL SURGERY DEVICE
6.1.2.4.1 PHOTOCOAGULATION LASER
6.1.2.4.2 ILLUMINATION DEVICE
6.1.2.4.3 VITRECTOMY MACHINE
6.2 BY VISION CARE
6.2.1 CONTACT LENS
6.2.2 SPECTACLES
6.2.3 EYE EXAMS
6.3 BY OPHTHALMIC DRUGS
6.3.1 BY PRESCRIPTION TYPE
6.3.1.1 PRESCRIPTION BASED OPHTHALMIC DRUGS
6.3.1.2 OTC (OVER THE COUNTER DRUGS)
6.3.2 BY DRUG DELIVERY TYPES
6.3.2.1 EYE DROPS
6.3.2.2 CAPSULES & TABLET
6.3.2.3 EYE OINTMENT
6.3.2.4 EYE GEL
6.3.2.5 EYE SOLUTION
6.4 BY TYPE OF DISEASE
6.4.1 GLAUCOMA
6.4.1.1 XALATAN (LATANOPROST)/XALACOM (LATANOPROST AND TIMOLOL COMBINATION) (XALABRANDS)
6.4.1.2 LUMIGAN FRANCHISE [LUMIGAN (BIMATOPROST) + GANFORT (BIMATOPROST AND TIMOLOL COMBINATION)]
6.4.1.3 TAPROS/TAFLOTAN (TAFLUPROST)
6.4.1.4 SAFLUTAN/ZIOPTAN (TAFLUPROST)
6.4.1.5 ALPHAGAN (BRIMONIDINE)/COMBIGAN (BRIMONIDINE AND TIMOLOL COMBINATION)
6.4.1.6 COSOPT (DORZOLAMIDE AND TIMOLOL COMBINATION)/ TRUSOPT (DORZOLAMIDE)
6.4.1.7 AZARGA (BRINZOLAMIDE AND TIMOLOL COMBINATION)
6.4.1.8 AZOPT (BRINZOLAMIDE)
6.4.2 RETINAL DISORDER
6.4.2.1 LUCENTIS (RANIBIZUMAB)
6.4.2.2 VISUDYNE (VERTEPORFIN)
6.4.2.3 AVASTIN (BEVACIZUMAB)
6.4.2.4 EYLEA (AFLIBERCEPT)
6.4.3 DRY EYE DRUG
6.4.3.1 RESTASIS (CYCLOSPORINE)
6.4.3.2 HYALEIN (SODIUM HYALURONATE)
6.4.3.3 DIQUAS (DIQUAFOSOL SODIUM)
6.4.4 ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUGS
6.4.4.1 PATANOL/PATADAY/OPATANOL (OLOPATADINE)
6.4.4.2 BEPREVE (BEPOTASTINE BESILATE)
6.4.4.3 TOBRADEX (TOBRAMYCIN & DEXAMETHASONE COMBINATION)
6.4.4.4 XIBROM/BROMDAY (BROMFENAC)
6.4.4.5 VIGAMOX
6.4.4.6 AZASITE (AZITHROMYCIN)
6.5 BY THERAPEUTICS
6.5.1 DIABETIC MACULAR EDEMA
6.5.2 EYE CANCER
6.5.3 DIABETIC RETINOPATHY
6.5.4 RETINAL VEIN OCCLUSION
6.5.5 AGE-RELATED MACULAR DEGENERATION
6.5.6 CONJUNCTIVITIS
6.5.7 DRY EYE
6.5.8 GLAUCOMA
6.5.9 KERATITIS
6.5.10 GEOGRAPHIC ATROPHY
6.6 BY END USER
6.6.1 HOSPITALS
6.6.2 EYE CLINICS
6.6.3 DIAGNOSTIC CENTERS
6.6.4 PATIENTS
7 KEY ANALYTICS
7.1 PORTER’S FIVE FORCE ANALYSIS
7.1.1 BARGAINING POWER BUYERS
7.1.2 BARGAINING POWER OF SUPPLIER
7.1.3 THREATS OF NEW ENTARANTS
7.1.4 THREATS OF SUBSTITUTES
7.1.5 COMPETITIVE RIVALRY
7.2 VALUE CHAIN ANALYSIS
7.2.1 SUPPLIERS
7.2.2 MANUFACTURERS
7.2.3 DISTRIBUTORS AND RETAILERS
7.2.4 END USER
7.3 KEY BUYING CRITERIA
7.4 KEY MARKET INSIGHTS
7.4.1 TOP 3 EMERGING COUNTRIES
7.4.2 TOP REVENUE GENERATING SEGMENTS
7.4.3 TOP GROWING MARKETS AND EMERGING TRENDS
7.4.4 R&D SCENARIO IN OPHTHALMOLOGY MARKET
7.4.4.1 PLASMA TECHNOLOGY IN OPHTHALMOLOGY
7.4.4.2 CORNIAL TOPOGRAPHY & CORNIAL ANALYSIS
7.4.4.3 SCOPE OF VIRTUAL REALITY TECHNOLOGY IN EYE CARE
7.5 SECTOR ANALYSIS
7.5.1 PARENT MARKET
7.5.2 SUB-SEGMENT MARKET
7.5.3 ALTERNATIVE MARKET
7.6 STRATEGIC RECOMMENDATION
7.7 STRATEGIC CONCLUSIONS
8 GEOGRAPHIC ANALYSIS
8.1 NORTH AMERICA
8.1.1 US
8.1.2 CANADA
9 COMPETITIVE LANDSCAPE
9.1 MARKET SHARE ANALYSIS
9.2 TOP WINNING STRATEGIES
9.3 CASE STUDIES: TOP COMPETITIVE MOVES
9.4 COMPANY PROFILES
9.4.1 ABBOTT LABORATORIES
9.4.2 AKORN
9.4.3 ALLERGAN INC.
9.4.4 BAYER AG
9.4.5 CIPLA PHARMACEUTICALS
9.4.6 EYEGATE PHARMACEUTICALS
9.4.7 EYEMED
9.4.8 GLAXOSMITHKLINE
9.4.9 JOHNSON AND JOHNSON
9.4.10 LPATH INCORPORATED
9.4.11 MERCK & CO.
9.4.12 BIOTECH VISIONCARE
9.4.13 CARL ZEISS MEDIATEK AG
9.4.14 ELLEX
9.4.15 NIDEK CO. LTD
9.4.16 NOVARTIS AG
9.4.17 PFIZER INC.
9.4.18 REGENERON
9.4.19 ROCHE HOLDING AG
9.4.20 SENJU PHARMACEUTICAL CO., LTD
9.4.21 SUN PHARMACEUTICALS INDUSTRIES, LTD.
9.4.22 SANTEN PHARMACEUTICAL CO.LTD
9.4.23 STAAR SURGICAL COMPANY
9.4.24 TOPCON CORPORATION
9.4.25 VALEANT
9.4.26 VISIONCARE OPHTHALMIC TECHNOLOGIES
9.4.27 ZIEMER OPHTHALMIC SYSTEMS AG
9.4.28 HAAG-STREIT GROUP
9.4.29 IRIDEX CORPORATION
1.1 STUDY GOALS
1.2 SCOPE OF MARKET STUDY
1.3 WHO WILL FIND THIS REPORT USEFUL?
1.4 STUDY AND FORECASTING YEARS
2 RESEARCH METHODOLOGY
2.1 SOURCES OF DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 TOP DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 DATA TRIANGULATION
3 EXECUTIVE SUMMARY
3.1 KEY FINDINGS
4 MARKET OVERVIEW
4.1 MARKET DEFINITION AND SCOPE
4.2 TOP OPHTHALMIC DRUGS BRANDS
5 MARKET DETERMINANTS
5.1 MARKET DRIVERS
5.1.1 INCREASING FDA APPROVALS GIVING A BOOST TO ADOPTION OF DRUGS AND DEVICES
5.1.2 SURGERIES IN OPHTHALMOLOGY MARKET ON RISE DUE TO HIGH PREVALENCE RATE OF REFRACTIVE ERRORS
5.1.3 INCREASING GERIATRIC POPULATION GLOBALLY
5.1.4 RISING PREVALENCE OF EYE DISORDERS
5.1.5 INCREASED HEALTHCARE EXPENDITURE
5.1.6 MINIMALLY INVASIVE SURGERIES ADOPTION ON RISE
5.2 MARKET RESTRAINTS
5.2.1 RENOWNED DRUGS GOING OFF PATENT
5.2.2 MAJOR PLAYERS AFFECTED BY DRYING PIPELINES
5.3 MARKET OPPORTUNITIES
5.3.1 GROWING OPPORTUNITIES IN DEVELOPING ECONOMIES
5.3.2 EMERGING MARKETS PRESENT REMARKABLE GROWTH OPPORTUNITIES
5.4 MARKET CHALLENGES
5.4.1 RISK ASSOCIATED WITH THE OCULAR DISEASES
5.4.2 LACK OF AWARENESS
6 MARKET SEGMENTATION
6.1 BY OPHTHALMIC DEVICES
6.1.1 DIAGNOSTIC & MONITORING EQUIPMENT
6.1.1.1 OPTICAL COHERENCE TOMOGRAPHY SCANNERS
6.1.1.2 OPHTHALMIC ULTRA SOUND IMAGING SYSTEMS
6.1.1.3 FUNDUS CAMERA
6.1.1.4 OPHTHALMOSCOPES
6.1.1.5 RETINOSCOPE
6.1.1.6 PACHYMETER
6.1.1.7 WAVEFRONT ABERROMETERS
6.1.1.8 PERIMETERS/VISUAL FIELD ANALYZER
6.1.1.9 AUTOREFRACTORS/PHOROPTER
6.1.1.10 KERATOMETERS
6.1.1.11 SPECULAR MICROSCOPE
6.1.1.12 CORNEAL TOPOGHAPHERS
6.1.1.13 TONOMETERS
6.1.1.14 SLIT LAMPS
6.1.1.15 BIOMETERS
6.1.1.16 OTHER
6.1.2 SURGERY DEVICE
6.1.2.1 CATARACT SURGERY DEVICE
6.1.2.1.1 INTRAOCULAR LENS
6.1.2.1.2 PHACOEMULSIFICATION DEVICES
6.1.2.1.3 OPHTHALMIC VISCOELASTIC DEVICES
6.1.2.2 GLAUCOMA SURGERY DEVICE
6.1.2.2.1 STENTS AND IMPLANT
6.1.2.2.2 GLAUCOMA DRAINAGE DEVICE
6.1.2.2.3 GLAUCOMA SYSTEM
6.1.2.2.4 GLAUCOMA LASER
6.1.2.3 REFRACTIVE SURGERY DEVICE
6.1.2.3.1 EXCIMER LASER
6.1.2.3.2 EMCROKERATOME
6.1.2.3.3 FEMTOSECOND LASER
6.1.2.3.4 YAG LASER
6.1.2.4 VITREORETINAL SURGERY DEVICE
6.1.2.4.1 PHOTOCOAGULATION LASER
6.1.2.4.2 ILLUMINATION DEVICE
6.1.2.4.3 VITRECTOMY MACHINE
6.2 BY VISION CARE
6.2.1 CONTACT LENS
6.2.2 SPECTACLES
6.2.3 EYE EXAMS
6.3 BY OPHTHALMIC DRUGS
6.3.1 BY PRESCRIPTION TYPE
6.3.1.1 PRESCRIPTION BASED OPHTHALMIC DRUGS
6.3.1.2 OTC (OVER THE COUNTER DRUGS)
6.3.2 BY DRUG DELIVERY TYPES
6.3.2.1 EYE DROPS
6.3.2.2 CAPSULES & TABLET
6.3.2.3 EYE OINTMENT
6.3.2.4 EYE GEL
6.3.2.5 EYE SOLUTION
6.4 BY TYPE OF DISEASE
6.4.1 GLAUCOMA
6.4.1.1 XALATAN (LATANOPROST)/XALACOM (LATANOPROST AND TIMOLOL COMBINATION) (XALABRANDS)
6.4.1.2 LUMIGAN FRANCHISE [LUMIGAN (BIMATOPROST) + GANFORT (BIMATOPROST AND TIMOLOL COMBINATION)]
6.4.1.3 TAPROS/TAFLOTAN (TAFLUPROST)
6.4.1.4 SAFLUTAN/ZIOPTAN (TAFLUPROST)
6.4.1.5 ALPHAGAN (BRIMONIDINE)/COMBIGAN (BRIMONIDINE AND TIMOLOL COMBINATION)
6.4.1.6 COSOPT (DORZOLAMIDE AND TIMOLOL COMBINATION)/ TRUSOPT (DORZOLAMIDE)
6.4.1.7 AZARGA (BRINZOLAMIDE AND TIMOLOL COMBINATION)
6.4.1.8 AZOPT (BRINZOLAMIDE)
6.4.2 RETINAL DISORDER
6.4.2.1 LUCENTIS (RANIBIZUMAB)
6.4.2.2 VISUDYNE (VERTEPORFIN)
6.4.2.3 AVASTIN (BEVACIZUMAB)
6.4.2.4 EYLEA (AFLIBERCEPT)
6.4.3 DRY EYE DRUG
6.4.3.1 RESTASIS (CYCLOSPORINE)
6.4.3.2 HYALEIN (SODIUM HYALURONATE)
6.4.3.3 DIQUAS (DIQUAFOSOL SODIUM)
6.4.4 ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUGS
6.4.4.1 PATANOL/PATADAY/OPATANOL (OLOPATADINE)
6.4.4.2 BEPREVE (BEPOTASTINE BESILATE)
6.4.4.3 TOBRADEX (TOBRAMYCIN & DEXAMETHASONE COMBINATION)
6.4.4.4 XIBROM/BROMDAY (BROMFENAC)
6.4.4.5 VIGAMOX
6.4.4.6 AZASITE (AZITHROMYCIN)
6.5 BY THERAPEUTICS
6.5.1 DIABETIC MACULAR EDEMA
6.5.2 EYE CANCER
6.5.3 DIABETIC RETINOPATHY
6.5.4 RETINAL VEIN OCCLUSION
6.5.5 AGE-RELATED MACULAR DEGENERATION
6.5.6 CONJUNCTIVITIS
6.5.7 DRY EYE
6.5.8 GLAUCOMA
6.5.9 KERATITIS
6.5.10 GEOGRAPHIC ATROPHY
6.6 BY END USER
6.6.1 HOSPITALS
6.6.2 EYE CLINICS
6.6.3 DIAGNOSTIC CENTERS
6.6.4 PATIENTS
7 KEY ANALYTICS
7.1 PORTER’S FIVE FORCE ANALYSIS
7.1.1 BARGAINING POWER BUYERS
7.1.2 BARGAINING POWER OF SUPPLIER
7.1.3 THREATS OF NEW ENTARANTS
7.1.4 THREATS OF SUBSTITUTES
7.1.5 COMPETITIVE RIVALRY
7.2 VALUE CHAIN ANALYSIS
7.2.1 SUPPLIERS
7.2.2 MANUFACTURERS
7.2.3 DISTRIBUTORS AND RETAILERS
7.2.4 END USER
7.3 KEY BUYING CRITERIA
7.4 KEY MARKET INSIGHTS
7.4.1 TOP 3 EMERGING COUNTRIES
7.4.2 TOP REVENUE GENERATING SEGMENTS
7.4.3 TOP GROWING MARKETS AND EMERGING TRENDS
7.4.4 R&D SCENARIO IN OPHTHALMOLOGY MARKET
7.4.4.1 PLASMA TECHNOLOGY IN OPHTHALMOLOGY
7.4.4.2 CORNIAL TOPOGRAPHY & CORNIAL ANALYSIS
7.4.4.3 SCOPE OF VIRTUAL REALITY TECHNOLOGY IN EYE CARE
7.5 SECTOR ANALYSIS
7.5.1 PARENT MARKET
7.5.2 SUB-SEGMENT MARKET
7.5.3 ALTERNATIVE MARKET
7.6 STRATEGIC RECOMMENDATION
7.7 STRATEGIC CONCLUSIONS
8 GEOGRAPHIC ANALYSIS
8.1 NORTH AMERICA
8.1.1 US
8.1.2 CANADA
9 COMPETITIVE LANDSCAPE
9.1 MARKET SHARE ANALYSIS
9.2 TOP WINNING STRATEGIES
9.3 CASE STUDIES: TOP COMPETITIVE MOVES
9.4 COMPANY PROFILES
9.4.1 ABBOTT LABORATORIES
9.4.2 AKORN
9.4.3 ALLERGAN INC.
9.4.4 BAYER AG
9.4.5 CIPLA PHARMACEUTICALS
9.4.6 EYEGATE PHARMACEUTICALS
9.4.7 EYEMED
9.4.8 GLAXOSMITHKLINE
9.4.9 JOHNSON AND JOHNSON
9.4.10 LPATH INCORPORATED
9.4.11 MERCK & CO.
9.4.12 BIOTECH VISIONCARE
9.4.13 CARL ZEISS MEDIATEK AG
9.4.14 ELLEX
9.4.15 NIDEK CO. LTD
9.4.16 NOVARTIS AG
9.4.17 PFIZER INC.
9.4.18 REGENERON
9.4.19 ROCHE HOLDING AG
9.4.20 SENJU PHARMACEUTICAL CO., LTD
9.4.21 SUN PHARMACEUTICALS INDUSTRIES, LTD.
9.4.22 SANTEN PHARMACEUTICAL CO.LTD
9.4.23 STAAR SURGICAL COMPANY
9.4.24 TOPCON CORPORATION
9.4.25 VALEANT
9.4.26 VISIONCARE OPHTHALMIC TECHNOLOGIES
9.4.27 ZIEMER OPHTHALMIC SYSTEMS AG
9.4.28 HAAG-STREIT GROUP
9.4.29 IRIDEX CORPORATION
LIST OF TABLES
TABLE 1 NORTH AMERICA OPHTHALMIC DRUGS AND DEVICE MARKET BY PRODUCT 2017-2025 ($ MILLION)
TABLE 2 TOP OPHTHALMIC DRUGS BRANDS
TABLE 3 DRUGS AND DEVICES APPROVED BY FDA
TABLE 4 SYMPTOMS OF SOME COMMON CAUSES OF LOSS OF VISION IN ELDERLY PATIENTS
TABLE 5 EYE DRUGS GONE PATENT OFF
TABLE 6 FACTS ABOUT CATARACT SURGERIES FROM DEVELOPING ECONOMIES
TABLE 7 NORTH AMERICA OPHTHALMIC DEVICE MARKET BY GEOGRAPHY 2017-2025($MILLION)
TABLE 8 NORTH AMERICA OPHTHALMIC DEVICE MARKET 2017-2025 ($ MILLION)
TABLE 9 NORTH AMERICA OPHTHALMIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET 2017-2025 ($ MILLION)
TABLE 10 SCANS PERFORMED BY DOMAINS
TABLE 11 DIFFERENCE BETWEEN A-SCAN AND B-SCAN SOUND WAVES GENERATION
TABLE 12 COMPARISON BETWEEN DIRECT AND INDIRECT OPHTHALMOSCOPY
TABLE 13 NORTH AMERICA OPHTHALMIC SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
TABLE 14 PATENT FOR ILLUMINATION SYSTEM IN OPHTHALMIC SURGERY 2015
TABLE 15 NORTH AMERICA VISION CARE MARKET BY DEVICE 2017-2025 ($ MILLION)
TABLE 16 EYE EXAMS AMONG VARIOUS AGE INDIVIDUALS
TABLE 17 VARIOUS FDA APPROVED DRUGS FOR OPHTHALMOLOGY
TABLE 18 FDA-APPROVED PRESCRIPTION DRUG INFORMATION
TABLE 19 OPHTHALMIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE
TABLE 20 NORTH AMERICA OPHTHALMOLOGY DRUG MARKET BY DELIVERY TYPES 2017-2025 ($ MILLION)
TABLE 21 TOP SELLING EYE DROPS 2016
TABLE 22 TOP SELLING EYE SUPPLEMENTS BRANDS IN US IN 2014
TABLE 23 TOP SELLING EYE OINTMENT IN US 2015
TABLE 24 TOP SELLING EYE SOLUTION IN US 2015
TABLE 25 NORTH AMERICA OPHTHALMIC DRUG AND DEVICE MARKET BY THERAPEUTICS 2017-2025 ($ MILLION)
TABLE 26 SYMPTOMS, TREATMENT, AND RECOVERY TIME FOR DIABETIC MACULAR EDEMA
TABLE 27 SYMPTOMS AND TREATMENT FOR EYE CANCER
TABLE 28 NORTH AMERICA OPHTHALMIC DRUGS & DEVICES MARKET BY END USER 2017-2025 ($ MILLION)
TABLE 29 APPLICATION OF VIRTUAL REALITY IN EYE CARE
TABLE 30 CASE STUDY OF VIRTUAL REALITY IN GLAUCOMA RESEARCH
TABLE 31 INITIATIVES FOR EYE CARE IN NORTH AMERICA
TABLE 32 NORTH AMERICA OPHTHALMIC DRUGS & DEVICES MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 33 US OPHTHALMIC DRUGS & DEVICE MARKET BY PRODUCT 2017-2025 ($ MILLION)
TABLE 34 US OPHTHALMIC DRUGS & DEVICES MARKET BY THERAPEUTICS 2017-2025 ($ MILLION)
TABLE 35 U.S. HOSPITAL FACT SHEET, 2016
TABLE 36 US OPHTHALMIC DEVICE MARKET BY TYPE 2017-2025($ MILLION)
TABLE 37 US VISION CARE DEVICES MARKET BY VISION CARE 2017-2025 ($ MILLION)
TABLE 38 US OPHTHALMIC DRUGS MARKET BY TYPE OF DISEASE 2017-2025 ($ MILLION)
TABLE 39 US OPHTHALMIC DRUGS MARKET BY DELIVERY TYPE 2017-2025($ MILLION)
TABLE 40 TOP WINNING STRATEGIES
TABLE 1 NORTH AMERICA OPHTHALMIC DRUGS AND DEVICE MARKET BY PRODUCT 2017-2025 ($ MILLION)
TABLE 2 TOP OPHTHALMIC DRUGS BRANDS
TABLE 3 DRUGS AND DEVICES APPROVED BY FDA
TABLE 4 SYMPTOMS OF SOME COMMON CAUSES OF LOSS OF VISION IN ELDERLY PATIENTS
TABLE 5 EYE DRUGS GONE PATENT OFF
TABLE 6 FACTS ABOUT CATARACT SURGERIES FROM DEVELOPING ECONOMIES
TABLE 7 NORTH AMERICA OPHTHALMIC DEVICE MARKET BY GEOGRAPHY 2017-2025($MILLION)
TABLE 8 NORTH AMERICA OPHTHALMIC DEVICE MARKET 2017-2025 ($ MILLION)
TABLE 9 NORTH AMERICA OPHTHALMIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET 2017-2025 ($ MILLION)
TABLE 10 SCANS PERFORMED BY DOMAINS
TABLE 11 DIFFERENCE BETWEEN A-SCAN AND B-SCAN SOUND WAVES GENERATION
TABLE 12 COMPARISON BETWEEN DIRECT AND INDIRECT OPHTHALMOSCOPY
TABLE 13 NORTH AMERICA OPHTHALMIC SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
TABLE 14 PATENT FOR ILLUMINATION SYSTEM IN OPHTHALMIC SURGERY 2015
TABLE 15 NORTH AMERICA VISION CARE MARKET BY DEVICE 2017-2025 ($ MILLION)
TABLE 16 EYE EXAMS AMONG VARIOUS AGE INDIVIDUALS
TABLE 17 VARIOUS FDA APPROVED DRUGS FOR OPHTHALMOLOGY
TABLE 18 FDA-APPROVED PRESCRIPTION DRUG INFORMATION
TABLE 19 OPHTHALMIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE
TABLE 20 NORTH AMERICA OPHTHALMOLOGY DRUG MARKET BY DELIVERY TYPES 2017-2025 ($ MILLION)
TABLE 21 TOP SELLING EYE DROPS 2016
TABLE 22 TOP SELLING EYE SUPPLEMENTS BRANDS IN US IN 2014
TABLE 23 TOP SELLING EYE OINTMENT IN US 2015
TABLE 24 TOP SELLING EYE SOLUTION IN US 2015
TABLE 25 NORTH AMERICA OPHTHALMIC DRUG AND DEVICE MARKET BY THERAPEUTICS 2017-2025 ($ MILLION)
TABLE 26 SYMPTOMS, TREATMENT, AND RECOVERY TIME FOR DIABETIC MACULAR EDEMA
TABLE 27 SYMPTOMS AND TREATMENT FOR EYE CANCER
TABLE 28 NORTH AMERICA OPHTHALMIC DRUGS & DEVICES MARKET BY END USER 2017-2025 ($ MILLION)
TABLE 29 APPLICATION OF VIRTUAL REALITY IN EYE CARE
TABLE 30 CASE STUDY OF VIRTUAL REALITY IN GLAUCOMA RESEARCH
TABLE 31 INITIATIVES FOR EYE CARE IN NORTH AMERICA
TABLE 32 NORTH AMERICA OPHTHALMIC DRUGS & DEVICES MARKET BY COUNTRIES 2017-2025 ($ MILLION)
TABLE 33 US OPHTHALMIC DRUGS & DEVICE MARKET BY PRODUCT 2017-2025 ($ MILLION)
TABLE 34 US OPHTHALMIC DRUGS & DEVICES MARKET BY THERAPEUTICS 2017-2025 ($ MILLION)
TABLE 35 U.S. HOSPITAL FACT SHEET, 2016
TABLE 36 US OPHTHALMIC DEVICE MARKET BY TYPE 2017-2025($ MILLION)
TABLE 37 US VISION CARE DEVICES MARKET BY VISION CARE 2017-2025 ($ MILLION)
TABLE 38 US OPHTHALMIC DRUGS MARKET BY TYPE OF DISEASE 2017-2025 ($ MILLION)
TABLE 39 US OPHTHALMIC DRUGS MARKET BY DELIVERY TYPE 2017-2025($ MILLION)
TABLE 40 TOP WINNING STRATEGIES
LIST OF FIGURES
FIGURE 1 KEY FINDINGS OF THE REPORT
FIGURE 2 PROJECTIONS FOR THE PROPORTION OF GLOBAL GERIATRIC (60+) POPULATION
FIGURE 3 WORLDWIDE PREVALENCE OF PRESBYOPIA (BILLION)
FIGURE 4 PREVALENCE OF GLAUCOMA AT GLOBAL LEVEL (MILLION)
FIGURE 5 HEALTHCARE EXPENDITURE OF DEVELOPED ECONOMIES AS % OF THEIR GDP IN 2014
FIGURE 6 HEALTHCARE EXPENDITURE OF DEVELOPING ECONOMIES AS % OF THEIR GDP IN 2014
FIGURE 7 HEALTHCARE EXPENDITURE (AS % OF GDP) OF MAJOR APAC COUNTRIES IN 2014
FIGURE 8 GROWTH IN GERIATRIC POPULATION FROM 2010 TO 2015(%)
FIGURE 9 RISK ASSOCIATED WITH THE OCULAR DISEASES
FIGURE 10 BLINDNESS CAUSES WORLDWIDE
FIGURE 11 NORTH AMERICA CATARACT SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 12 NORTH AMERICA GLAUCOMA SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 13 NORTH AMERICA REFRACTIVE SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 14 NORTH AMERICA VITREORETINAL SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 15 NORTH AMERICA CONTACT LENS MARKET 2017-2025 ($ MILLION)
FIGURE 16 CONTACT LENS USAGE AMONG VARIOUS AGE GROUPS IN THE U.S. 2015
FIGURE 17 NORTH AMERICA SPECTACLES MARKET 2017-2025 ($ MILLION)
FIGURE 18 EYE EXAMS IN THE U.S. ADULTS 2012-2014 (MILLION)
FIGURE 19 CONSUMPTION OF DRUGS BY TYPES IN 2016
FIGURE 20 NORTH AMERICA EYE DROPS MARKET 2017-2025 ($ MILLION)
FIGURE 21 USAGE OF EYE DROPS AND EYE WASH IN U.S. HOUSEHOLDS 2012-2015 (%)
FIGURE 22 NORTH AMERICA CAPSULES & TABLET MARKET 2017-2025 ($ MILLION)
FIGURE 23 NORTH AMERICA EYE OINTMENT MARKET 2017-2025 ($ MILLION)
FIGURE 24 NORTH AMERICA EYE GEL MARKET 2017-2025 ($ MILLION)
FIGURE 25 NORTH AMERICA EYE SOLUTION MARKET 2017-2025 ($ MILLION)
FIGURE 26 NORTH AMERICA GLAUCOMA DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 27 DIFFERENT AGE GROUP WITH PROBABILITY OF BEING AFFECTED 2016
FIGURE 28 NORTH AMERICA RETINAL DISORDER DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 29 NORTH AMERICA DRY EYE DRUG MARKET 2017-2025($ MILLION)
FIGURE 30 NORTH AMERICA ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 31 DIABETIC RETINOPATHY PREVALENCE IN THE U.S. 2011 & 2030 (MILLION)
FIGURE 32 TOTAL OPHTHALMIC CARE HOSPITAL IN US 2014
FIGURE 33 EYE DISEASES CASES ABOVE AGE OF 40 IN AMERICA 2014 (MILLION)
FIGURE 34 TOTAL VISUAL IMPAIRMENT AND BLINDNESS CASES ABOVE AGE 40 IN US IN 2014 (MILLION)
FIGURE 35 CASES ABOVE 40 AGE IN AMERICA 2014 (MILLION)
FIGURE 36 VALUE CHAIN ANALYSIS: OPHTHALMIC DRUGS MARKET
FIGURE 37 VALUE CHAIN ANALYSIS OF OPHTHALMIC DEVICES MARKET
FIGURE 38 KEY BUYING CRITERIA
FIGURE 39 KEY BUYING CRITERIA IMPACT
FIGURE 40 TOP REVENUE GENERATING SEGMENTS 2017-2025 ($ MILLION)
FIGURE 41 BENEFITS SUPPORTING HIGHER CATARACT SURGERIES
FIGURE 42 MAJOR RESEARCH AND DEVELOPMENT AREAS IN PLASMA TECHNOLOGY IN OPHTHALMOLOGY
FIGURE 43 NUMBER OF CLINICS USING VR SYSTEMS IN VARIOUS GEOGRAPHIES
FIGURE 44 KEY MARKET FACTS
FIGURE 45 VISION SCREENING PERFORMED BY EACH GROUP OF PROVIDERS (IN %)
FIGURE 46 ATTRACTIVE INVESTMENT PROPOSITION BY SEGMENT 2016 ($ MILLION)
FIGURE 47 ATTRACTIVE INVESTMENT PROPOSITION BY GEOGRAPHY 2016 ($ MILLION)
FIGURE 48 UNITED STATES (U.S.) MARKET 2017-2025 ($ MILLION)
FIGURE 49 CAUSES OF VISUAL IMPAIRMENT IN THE U.S. 2016
FIGURE 50 PREVALENCE RATE OF RETINAL DISORDERS IN CANADA, 2016
FIGURE 51 FINANCIAL COST SHARE OF RETINA DISORDER TREATMENT IN CANADA
FIGURE 1 KEY FINDINGS OF THE REPORT
FIGURE 2 PROJECTIONS FOR THE PROPORTION OF GLOBAL GERIATRIC (60+) POPULATION
FIGURE 3 WORLDWIDE PREVALENCE OF PRESBYOPIA (BILLION)
FIGURE 4 PREVALENCE OF GLAUCOMA AT GLOBAL LEVEL (MILLION)
FIGURE 5 HEALTHCARE EXPENDITURE OF DEVELOPED ECONOMIES AS % OF THEIR GDP IN 2014
FIGURE 6 HEALTHCARE EXPENDITURE OF DEVELOPING ECONOMIES AS % OF THEIR GDP IN 2014
FIGURE 7 HEALTHCARE EXPENDITURE (AS % OF GDP) OF MAJOR APAC COUNTRIES IN 2014
FIGURE 8 GROWTH IN GERIATRIC POPULATION FROM 2010 TO 2015(%)
FIGURE 9 RISK ASSOCIATED WITH THE OCULAR DISEASES
FIGURE 10 BLINDNESS CAUSES WORLDWIDE
FIGURE 11 NORTH AMERICA CATARACT SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 12 NORTH AMERICA GLAUCOMA SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 13 NORTH AMERICA REFRACTIVE SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 14 NORTH AMERICA VITREORETINAL SURGERY DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 15 NORTH AMERICA CONTACT LENS MARKET 2017-2025 ($ MILLION)
FIGURE 16 CONTACT LENS USAGE AMONG VARIOUS AGE GROUPS IN THE U.S. 2015
FIGURE 17 NORTH AMERICA SPECTACLES MARKET 2017-2025 ($ MILLION)
FIGURE 18 EYE EXAMS IN THE U.S. ADULTS 2012-2014 (MILLION)
FIGURE 19 CONSUMPTION OF DRUGS BY TYPES IN 2016
FIGURE 20 NORTH AMERICA EYE DROPS MARKET 2017-2025 ($ MILLION)
FIGURE 21 USAGE OF EYE DROPS AND EYE WASH IN U.S. HOUSEHOLDS 2012-2015 (%)
FIGURE 22 NORTH AMERICA CAPSULES & TABLET MARKET 2017-2025 ($ MILLION)
FIGURE 23 NORTH AMERICA EYE OINTMENT MARKET 2017-2025 ($ MILLION)
FIGURE 24 NORTH AMERICA EYE GEL MARKET 2017-2025 ($ MILLION)
FIGURE 25 NORTH AMERICA EYE SOLUTION MARKET 2017-2025 ($ MILLION)
FIGURE 26 NORTH AMERICA GLAUCOMA DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 27 DIFFERENT AGE GROUP WITH PROBABILITY OF BEING AFFECTED 2016
FIGURE 28 NORTH AMERICA RETINAL DISORDER DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 29 NORTH AMERICA DRY EYE DRUG MARKET 2017-2025($ MILLION)
FIGURE 30 NORTH AMERICA ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 31 DIABETIC RETINOPATHY PREVALENCE IN THE U.S. 2011 & 2030 (MILLION)
FIGURE 32 TOTAL OPHTHALMIC CARE HOSPITAL IN US 2014
FIGURE 33 EYE DISEASES CASES ABOVE AGE OF 40 IN AMERICA 2014 (MILLION)
FIGURE 34 TOTAL VISUAL IMPAIRMENT AND BLINDNESS CASES ABOVE AGE 40 IN US IN 2014 (MILLION)
FIGURE 35 CASES ABOVE 40 AGE IN AMERICA 2014 (MILLION)
FIGURE 36 VALUE CHAIN ANALYSIS: OPHTHALMIC DRUGS MARKET
FIGURE 37 VALUE CHAIN ANALYSIS OF OPHTHALMIC DEVICES MARKET
FIGURE 38 KEY BUYING CRITERIA
FIGURE 39 KEY BUYING CRITERIA IMPACT
FIGURE 40 TOP REVENUE GENERATING SEGMENTS 2017-2025 ($ MILLION)
FIGURE 41 BENEFITS SUPPORTING HIGHER CATARACT SURGERIES
FIGURE 42 MAJOR RESEARCH AND DEVELOPMENT AREAS IN PLASMA TECHNOLOGY IN OPHTHALMOLOGY
FIGURE 43 NUMBER OF CLINICS USING VR SYSTEMS IN VARIOUS GEOGRAPHIES
FIGURE 44 KEY MARKET FACTS
FIGURE 45 VISION SCREENING PERFORMED BY EACH GROUP OF PROVIDERS (IN %)
FIGURE 46 ATTRACTIVE INVESTMENT PROPOSITION BY SEGMENT 2016 ($ MILLION)
FIGURE 47 ATTRACTIVE INVESTMENT PROPOSITION BY GEOGRAPHY 2016 ($ MILLION)
FIGURE 48 UNITED STATES (U.S.) MARKET 2017-2025 ($ MILLION)
FIGURE 49 CAUSES OF VISUAL IMPAIRMENT IN THE U.S. 2016
FIGURE 50 PREVALENCE RATE OF RETINAL DISORDERS IN CANADA, 2016
FIGURE 51 FINANCIAL COST SHARE OF RETINA DISORDER TREATMENT IN CANADA
